Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgeto
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Pittcon 2015, the 66th Conference and ... March 12, in New Orleans with an economic impact ... by the New Orleans Convention and Visitor's Bureau. This ... exhibitor personnel. Those who attended Pittcon for the ... the third year, the co-location of Food Labs Conference, ...
(Date:3/31/2015)... , March 31, 2015   Mapi ... integrating Mapi,s Medical Affairs and global Risk Management ... a previously announced acquisition . ... are conducted by a global team that includes ... have decades of experience in navigating complex safety ...
(Date:3/31/2015)...  University of Illinois, Swanlund ... plenary session address on Monday, May 18 at the ... kicking off a week of more than 160 technical ... RF and microwave technologies with health. Dr. ... Circuits for the Skin," will focus on the experimental ...
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has received ... States patent has recently been allowed for the Company’s ... “Lipid Construct for Delivery of Insulin to a Mammal,” ... the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) ... effectively reach the liver’s metabolic cells, called hepatocytes. , ...
Breaking Biology Technology:Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Health and Engineering Converge at the 2015 International Microwave Symposium 2Health and Engineering Converge at the 2015 International Microwave Symposium 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2
... March 29, 2011 Perceptive Informatics , a ... International Corporation (Nasdaq: PRXL ), today unveiled ... (EDC) solution, which provides richer functionality to further streamline ... solution enables clinical trial sponsors to more efficiently ...
... MP3s, smartphones and cameras could become a reality thanks ... a tiny device that improves on existing forms of ... to convert data into signals that are stored as ... arm to translate the data into electrical signals. This ...
... MARIETTA, Ga., March 28, 2011 MiMedx Group, Inc. ... developer, manufacturer and marketer of patent protected biomaterial-based products ... its results for the year ended December 31, 2010. ... Company changed its fiscal year to coincide with the ...
Cached Biology Technology:Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 2Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 3Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 4Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 5MiMedx Group Announces 2010 Results 2MiMedx Group Announces 2010 Results 3MiMedx Group Announces 2010 Results 4MiMedx Group Announces 2010 Results 5MiMedx Group Announces 2010 Results 6MiMedx Group Announces 2010 Results 7
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Karolinska Institutet have been able to describe the 3D structure ... beginning of fertilization. The results, published in the journal ... may enable entirely new types of contraceptives. For centuries, ... of gametes egg and sperm-, whose union gives rise ...
... in Spanish . Ikerlan-IK4 and Mondragn ... Spanish National Research Council, CSIC, and which has developed a ... blood stream by means of ultrasonic waves. The Foundation General ... Carrato, has also collaborated on this project. The patented ...
... Thursday, Oct. 21, will be the world,s first recipient ... vertigo associated with Meniere,s disease. The UW ... success in a 10-person surgical trial of Meniere,s patients ... common balance disorders that torment millions of people worldwide. ...
Cached Biology News:Researchers develop first implanted device to treat balance disorder 2Researchers develop first implanted device to treat balance disorder 3
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
... selects single cells, or clusters, with rapid, ... all, a single cell can be targeted, ... collected into the pipette, and automatically transferred ... plate. Quixells unique aspiration and expulsion system ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Maize microRNA Microarray contains ...
... The LTQ XL extends the legendary MSn ... to generate structural information through Thermo Scientifics ... Scientific's LTQ XL is the only mass ... ETD and CID. Pulsed Q Collision ...
Biology Products: